Resultados de Búsqueda por Autor

1

artículo

The Latin American experience of allografting patients with severe aplastic anaemia: Real-world data on the impact of stem cell source and ATG administration in HLA-identical sibli...

Publicado por
Gómez-Almaguer, D., Vázquez-Mellado, A., Navarro-Cabrera, J.R., Abello-Polo, V., Milovic, V., García, J., Basquiera, A.L., Saba, S., Vela-Ojeda, J., Gómez, S., Karduss-Aurueta, A., Bustinza-Álvarez, A., Requejo, A., Feldman, L., Jaime-Pérez, J.C., Yantorno, S., Kusminsky, G., Gutiérrez-Aguirre, CH, Arbelbide, J., Martinez-Rolon, J., Jarchum, G., Jaimovich, G., Riera, L., Pedraza-Mesa, E., Villamizar-Gómez, L., Herrera-Rojas, M.A., Gamboa-Alonso, M.M., Foncuberta, C., Rodríguez-González, G., García Ruiz-Esparza, M.A., Hernández-Maldonado, E., Paz-Infanzón, M., González-López, E., Ruiz-Argüelles, G.J.

Publicado 2017

Enlace

Se estudió los casos de 298 pacientes con anemia aplásica severa aloinjertados, en cuatro países de América Latina: Argentina, México, Perú y Colombia. Se proporciona datos reales del impacto de la administración de fuente de células madre y de globulina antitimocito en el trasplante de hermanos con idéntico Antígeno leucocitario humano.

2

artículo

Patients Age 40 Years and Younger with Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients' Evidence from Latin America

Publicado por
Martinez-Cordero, H, Peña, C, Schutz, NP, Bove, V, Villano, F, Beltran, C, Donoso, J, Lopez-Vidal, H, Roa-Salinas, MA, Soto, P, Ochoa, P, Duarte, P, Remaggi, G, Corzo, A, Shanley, C, Lopresti, S, Orlando, S, Verri, V, Quiroga, LD, Fantl, D, Ramirez, J, Ospina-Idarraga, A, Idrobo, H, Quintero, G, Gomez, R, Cantu-Martinez, O, Gomez-Almaguer, D, Ruiz-Arguelles, GJ, Galvez-Cardenas, KM, Salazar, LA, Novoa-Caicedo, I, Fuentes-Lacouture, MC, Spirko, P, Arbelaez, MI, Pereira, M, Valdes, J, Vasquez, J, Von-Glasenapp, A, Riva, E

Publicado 2023

Enlace

PURPOSEMultiple myeloma (MM) is a highly heterogeneous, incurable disease most frequently diagnosed in the elderly. Therefore, data on clinical characteristics and outcomes in the very young population are scarce.PATIENTS AND METHODSWe analyzed clinical characteristics, response to treatment, and survival in 103 patients with newly diagnosed MM age 40 years or younger compared with 256 patients age 41-50 years and 957 patients age 51 years or older.RESULTSThere were no statistical differences in sex, isotype, International Scoring System, renal involvement, hypercalcemia, anemia, dialysis, bony lesions, extramedullary disease, and lactate dehydrogenase (LDH). The most used regimen in young patients was cyclophosphamide, bortezomib, dexamethasone, followed by cyclophosphamide, thalidomide, dexamethasone and bortezomib, thalidomide, dexamethasone. Of the patients age 40 years or younger, o...

3

artículo

Treating Acute Leukemia During the COVID-19 Pandemic in an Environment With Limited Resources: A Multicenter Experience in Four Latin American Countries

Publicado por
Demichelis-Gómez, R, Alvarado-Ibarra, M, Vasquez-Chávez, J, Delgado-López, N, Gómez-Cortés, C, Espinosa-Bautista, K, Cooke-Tapia, A, Milán-Salvatierra, A, Gómez-De León, A, Lee-Tsai, YL, Rosales-López, D, Cabrera-García, Á, Amador-Medina, F, Córdoba-Ramírez, A, Murrieta-Álvarez, I, Solís-Poblano, JC, Apodaca-Chávez, E, Rangel-Patiño, J, Álvarez-Vera, JL, Arana-Luna, L, De la Peña-Celaya, JA, Espitia-Ríos, ME, Hernández-Ruiz, E, Pérez-Zúñiga, JM, Peña-López, E, González-Rivera, R, García-Leyva, MF, Tejeda-Romero, M, Cruz-Rico, J, Balderas-Delgado, C, Ruíz-Argüelles, GJ, Gómez-Almaguer, D

Publicado 2021

Enlace

Purpose: The COVID-19 pandemic is a colossal challenge for global health; nonetheless, specific subgroups face considerably higher risks for infection and mortality. Among patients with malignant diseases, those with hematologic neoplasms are at a higher risk for poor outcomes. The objective of this study was to register treatment modifications associated with the COVID-19 pandemic and their short-term consequences in Latin America.Methods: Multicenter, prospective, observational, cohort study including patients older than 14 years from 14 centers in four countries (Mexico, Peru, Guatemala, and Panama) who had a confirmed diagnosis of acute leukemia, and who were undergoing active treatment since the first COVID-19 case in each country until the cutoff on July 15, 2020.Results: We recruited 635 patients. Treatment modifications because of the COVID-19 pandemic were reported in 40.8% of c...

4

artículo

Treating Acute Leukemia During the COVID-19 Pandemic in an Environment With Limited Resources: A Multicenter Experience in Four Latin American Countries

Publicado por
Demichelis-Gómez, R, Alvarado-Ibarra, M, Vasquez-Chávez, J, Delgado-López, N, Gómez-Cortés, C, Espinosa-Bautista, K, Cooke-Tapia, A, Milán-Salvatierra, A, Gómez-De León, A, Lee-Tsai, YL, Rosales-López, D, Cabrera-García, Á, Amador-Medina, F, Córdoba-Ramírez, A, Murrieta-Álvarez, I, Solís-Poblano, JC, Apodaca-Chávez, E, Rangel-Patiño, J, Álvarez-Vera, JL, Arana-Luna, L, De la Peña-Celaya, JA, Espitia-Ríos, ME, Hernández-Ruiz, E, Pérez-Zúñiga, JM, Peña-López, E, González-Rivera, R, García-Leyva, MF, Tejeda-Romero, M, Cruz-Rico, J, Balderas-Delgado, C, Ruíz-Argüelles, GJ, Gómez-Almaguer, D

Publicado 2021

Enlace

Purpose: The COVID-19 pandemic is a colossal challenge for global health; nonetheless, specific subgroups face considerably higher risks for infection and mortality. Among patients with malignant diseases, those with hematologic neoplasms are at a higher risk for poor outcomes. The objective of this study was to register treatment modifications associated with the COVID-19 pandemic and their short-term consequences in Latin America. Methods: Multicenter, prospective, observational, cohort study including patients older than 14 years from 14 centers in four countries (Mexico, Peru, Guatemala, and Panama) who had a confirmed diagnosis of acute leukemia, and who were undergoing active treatment since the first COVID-19 case in each country until the cutoff on July 15, 2020. Results: We recruited 635 patients. Treatment modifications because of the COVID-19 pandemic were reported in 40.8% of...